According to filings with the U.S. Securities and Exchange Commission, Andson Biotech is raising up to $3,600,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Mason Chilmonczyk played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Andson Biotech
Andson Biotechnology is building novel process analytical technologies (PATs) for application to modern biopharmaceutical workflows. Andson is leveraging novel approaches to inline and at-line mass spectrometric analysis to enable discovery, development, and process improvement with advanced analytics. We are still pre-launch, but we are open to exploring how we can work together as we deploy our first product. If you are developing or producing any type of bio-based therapeutic we want to help you! Our technology can provide unparalleled process insight for novel quality indicators, new process understanding, and improved outcomes.

To learn more about Andson Biotech, visit http://www.andsonbiotech.com/

Contact:
Mason Chilmonczyk, Chief Executive Officer
727-389-7725

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.